Tecentriq Approved for Small Cell Lung Cancer
The drug has been approved as a first-line treatment for the disease, to be used in combination with the chemotherapy drugs carboplatin and etoposide.
Tecentriq was evaluated in a clinical study involving 403 adults who had received no prior chemotherapy, the FDA said in a news release.
Average survival for those who took the Tecentriq combination was 12.3 months, compared to 10.3 months among those who took the chemotherapy drugs and a placebo.
The most common side effects among the Tecentriq group were fatigue, nausea, temporary baldness, constipation and loss of appetite.
The newly approved drug is produced by Genentech, based in South San Francisco.
© 2020 HealthDay. All rights reserved.
Posted: March 2019
Read this next
THURSDAY, Oct. 1, 2020 -- A newly approved drug for the leading form of the number one cancer killer, lung cancer, does improve patient survival, a new study confirms. The...
WEDNESDAY, Aug. 12, 2020 -- Fewer Americans have been dying of lung cancer in recent years -- partly because of advances in treatment, a new government study finds. The...
THURSDAY, July 23, 2020 -- Scientists are working on a blood test that may catch five common cancers years sooner than current methods. The blood test, which is still...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.